1. Home
  2. FTHM vs MURA Comparison

FTHM vs MURA Comparison

Compare FTHM & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fathom Holdings Inc.

FTHM

Fathom Holdings Inc.

HOLD

Current Price

$1.12

Market Cap

37.9M

Sector

Finance

ML Signal

HOLD

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.03

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTHM
MURA
Founded
2010
2013
Country
United States
Ireland
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
36.0M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
FTHM
MURA
Price
$1.12
$2.03
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$2.50
$6.00
AVG Volume (30 Days)
115.2K
224.8K
Earning Date
11-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$421,612,000.00
N/A
Revenue This Year
$30.07
N/A
Revenue Next Year
$14.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.78
N/A
52 Week Low
$0.65
$0.95
52 Week High
$3.37
$4.74

Technical Indicators

Market Signals
Indicator
FTHM
MURA
Relative Strength Index (RSI) 40.42 40.39
Support Level $1.16 $2.06
Resistance Level $1.27 $2.10
Average True Range (ATR) 0.07 0.01
MACD 0.02 -0.01
Stochastic Oscillator 8.73 25.00

Price Performance

Historical Comparison
FTHM
MURA

About FTHM Fathom Holdings Inc.

Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: